ERBB2 and neoplasm: High level of immune infiltration in the primary tumor, measured by the number of TILs or immune gene expression signatures, has been associated with longer survival and response to neoadjuvant chemotherapy in triple-negative and HER2 positive breast cancers (not in luminal A breast cancers) [34–43].